IR@PKUHSC  > 北京大学第一临床医学院  > 消化科
学科主题临床医学
Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells
Peng, Meiyu1,2,3,4; Huang, Bingqing1,2,3; Zhang, Qi5; Fu, Shuyu1,2,3; Wang, Dan1,2,3; Cheng, Xixi1,2,3; Wu, Xi1,2,3; Xue, Zhenyi1,2,3; Zhang, Lijuan1,2,3; Zhang, Da6; Da, Yurong1,2; Dai, Yun3,7; Yang, Qing8; Yao, Zhi1,2,3; Qiao, Liang9; Zhang, Rongxin1,2,3
关键词Pancreatic cancer Embelin Inflammation IL-6 MDSCs
刊名CANCER LETTERS
2014-11-28
DOI10.1016/j.canlet.2014.08.011
354期:2页:407-416
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者Chinese Ministry of Science and Technology ; National Natural Science Foundation of China ; Chinese Ministry of Science and Technology ; National Natural Science Foundation of China
研究领域[WOS]Oncology
关键词[WOS]TH17 CELLS ; ACTIVATION ; DIFFERENTIATION ; CONTRIBUTES ; TUMORS ; CSF
英文摘要

Pancreatic cancer is an aggressive malignancy and unresponsive to conventional chemotherapies. Here, the anti-inflammatory and anti-tumor effects of embelin on pancreatic cancer were investigated. Embelin significantly attenuated cells invasion, proliferation and induced apoptosis through inhibition of STAT3 and activation of p53 signaling pathways. Embelin substantially reduced the tumorigenicity of pancreatic cancer cells in vivo, which was associated with reduced inflammatory cells and immune suppressive cells, IL-17A(+) Th17, GM-CSF+ Th, MDSCs and Treg, through inhibition of IL-6 secretion. Moreover, embelin decrease IL-6-induced STAT3 phosphorylation. In summary, embelin represents a novel therapeutic drug candidate for the clinical treatment of pancreatic cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

语种英语
所属项目编号2012CB932503 ; 2011CB933100 ; 91029705 ; 81172864 ; 81272317 ; 81371644 ; 81072019
资助者Chinese Ministry of Science and Technology ; National Natural Science Foundation of China ; Chinese Ministry of Science and Technology ; National Natural Science Foundation of China
WOS记录号WOS:000344127600022
引用统计
被引频次:9[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65892
专题北京大学第一临床医学院_消化科
作者单位1.Weifang Med Univ, Basic Med Coll, Dept Immunol, Weifang, Peoples R China
2.Tianjin Med Univ, Res Ctr Basic Med Sci, Lab Immunol & Inflammat, Tianjin, Peoples R China
3.Tianjin Med Univ, Basic Med Coll, Dept Immunol, Tianjin, Peoples R China
4.Tianjin Med Univ, Key Lab Immune Microenvironm & Dis, Educ Minist China, Tianjin, Peoples R China
5.Tianjin Med Univ, Sch Basic Med Sci, Dept Pharmacol, Tianjin, Peoples R China
6.Tianjin Med Univ, Sch Med Imaging, Tianjin 300070, Peoples R China
7.Peking Univ, Hosp 1, Dept Gastroenterol, Beijing, Peoples R China
8.Tianjin Med Univ, Canc Hosp, Dept Genitourinary Oncol, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
9.Univ Sydney, Westmead Hosp, Western Clin Sch, Westmead Millennium Inst,Storr Liver Unit, Westmead, NSW 2145, Australia
推荐引用方式
GB/T 7714
Peng, Meiyu,Huang, Bingqing,Zhang, Qi,et al. Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells[J]. CANCER LETTERS,2014,354(2):407-416.
APA Peng, Meiyu.,Huang, Bingqing.,Zhang, Qi.,Fu, Shuyu.,Wang, Dan.,...&Zhang, Rongxin.(2014).Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells.CANCER LETTERS,354(2),407-416.
MLA Peng, Meiyu,et al."Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells".CANCER LETTERS 354.2(2014):407-416.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Peng, Meiyu]的文章
[Huang, Bingqing]的文章
[Zhang, Qi]的文章
百度学术
百度学术中相似的文章
[Peng, Meiyu]的文章
[Huang, Bingqing]的文章
[Zhang, Qi]的文章
必应学术
必应学术中相似的文章
[Peng, Meiyu]的文章
[Huang, Bingqing]的文章
[Zhang, Qi]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。